by Corryn Wetzel/Smithsonianmag.com
A panel of independent advisers to the Food and Drug Administration (FDA) recommended yesterday that regulators authorize a lower-dose version of the Pfizer-BioNTech Covid-19 vaccine for 5- to 11-year-olds. The announcement brings about 28 million children closer to being vaccinated against Covid-19, a move many parents and public health officials have been eagerly awaiting.
The FDA panel reviewed Pfizer’s study of 1,518 children who received two doses of the 10-microgram vaccine and found the vaccine was around 91 percent effective in preventing symptomatic Covid-19 infections in young kids, according to Matthew Herper and Helen Branswell for STAT. The Pfizer vaccine for young children contains one-third the dose of an adult shot and would be given 21 days or more after their first shot. The company’s lower-dose vaccine prompts a strong immune response while minimizing side effects, according to Pfizer.
“We don’t want children to be dying from Covid, even if it is far fewer children than adults, and we don’t want them in the ICU,” said Amanda Cohn, a panel member and Centers for Disease Control and Prevention (CDC) vaccine official, during yesterday’s virtual committee hearing. She noted that Covid-19 is “the eighth-highest killer of kids in this age group over the past year.”
Carol graduated from Riverside White Cross School of Nursing in Columbus, Ohio and received her diploma as a registered nurse. She attended Bowling Green State University where she received a Bachelor of Arts Degree in History and Literature. She attended the University of Toledo, College of Nursing, and received a Master’s of Nursing Science Degree as an Educator.
She has traveled extensively, is a photographer, and writes on medical issues. Carol has three children RJ, Katherine, and Stephen – one daughter-in-law; Katie – two granddaughters; Isabella Marianna and Zoe Olivia – and one grandson, Alexander Paul. She also shares her life with her husband Gordon Duff, many cats, and two rescues.